Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Reports Q1 2024 Tentative Revenue of KRW 736.9 Billion (+23.33% YoY) and Operating Profit of KRW 15.4 Billion (-91.54% YoY)

Posted on May 9, 2024July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Reports Q1 2024 Tentative Revenue of KRW 736.9 Billion (+23.33% YoY) and Operating Profit of KRW 15.4 Billion (-91.54% YoY)

Fact Source: Financial Supervisory Service (DART) / 2024-05-09

Disclosure Type: Consolidated Tentative Earnings Results (Fair Disclosure)

💡 3-Second Summary

Celltrion’s tentative consolidated revenue for Q1 2024 increased by 23.33% YoY to KRW 736.9 billion, while its operating profit fell by 91.54% YoY to KRW 15.4 billion.

📊 1. [Summary of Core Disclosure Content and Major Figures]

  • Q1 2024 Consolidated Tentative Earnings (Unit: KRW Million, %):
    • Revenue: KRW 736,980 million (approx. KRW 736.9B)
      • Compared to previous quarter (Q4 2023): +92.63%
      • Compared to same period last year (Q1 2023): +23.33%
    • Operating Profit: KRW 15,437 million (approx. KRW 15.4B)
      • Compared to previous quarter (Q4 2023): -16.21%
      • Compared to same period last year (Q1 2023): -91.54%
    • Profit Before Income Tax: KRW 19,678 million (approx. KRW 19.6B)
      • Compared to previous quarter (Q4 2023): Turned to black (Q4 2023: KRW -9,776 million)
      • Compared to same period last year (Q1 2023): -90.55%
    • Net Profit: KRW 20,768 million (approx. KRW 20.7B)
      • Compared to previous quarter (Q4 2023): +4,484.55% (Q4 2023: KRW 453 million)
      • Compared to same period last year (Q1 2023): -87.57%
    • Net Profit Attributable to Owners of Parent: KRW 22,438 million (approx. KRW 22.4B)
      • Compared to previous quarter (Q4 2023): +2,028.84% (Q4 2023: KRW 1,054 million)
      • Compared to same period last year (Q1 2023): -86.42%
  • Cumulative Figures: As these are tentative results for Q1, the current quarter performance figures are identical to the cumulative numbers.
  • Details of Information Provision: Information was presented on May 9, 2024, to domestic and foreign investors and media by the IR department.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

  • Divergence Between Revenue Growth and Profitability Decline: The most notable aspect of this tentative disclosure is the significant gap between top-line expansion and bottom-line contraction. While quarterly revenue expanded by 92.63% QoQ and 23.33% YoY, operating profit fell by 91.54% YoY to KRW 15.4 billion.
  • Sequential Recovery in Net Profit: Despite the weak operating performance, profit before income tax turned profitable compared to the previous quarter, and net profit (KRW 20,768 million) and net profit attributable to parent (KRW 22,438 million) grew sharply on a quarter-over-quarter basis. However, compared to Q1 2023, these figures represent declines of 87.57% and 86.42%, respectively.
  • No Specific Causes Listed in Disclosure: This filing outlines the preliminary financial figures and does not specify the cost components, segment performances, or concrete reasons for the decrease in operating profit. Therefore, a comprehensive assessment requires aligning these numbers with official IR presentation materials and the subsequent finalized audit report.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s tentative Q1 2024 financial results present a stark contrast between growing business volume and diminished profitability. While the company demonstrated strong top-line expansion, surpassing KRW 736.9 billion with double-digit year-over-year growth, its operating profit recorded a steep contraction, declining by over 91% compared to the same period last year to approximately KRW 15.4 billion.

Because this filing is a preliminary disclosure based on internal accounting, it contains only the numeric results and does not explain the operational causes behind the margin compression. Consequently, key checkpoints for investors going forward include verifying any adjustments in the finalized audited financials and analyzing the specific cost factors—such as cost of goods sold (COGS), selling, general, and administrative (SG&A) expenses, or one-off items—through subsequent investor relations (IR) disclosures.

📢 Disclaimer & Source Information

Source: This content was restructured and newly drafted based on the official submitted data from the Financial Supervisory Service (DART).

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Bio & Healthcare, Disclosures

Post navigation

Previous Post: [Disclosure] Celltrion (068270) to Additionally List 63,385 Common Shares Following Exercise of Stock Options
Next Post: [Disclosure] Wonik IPS (Ticker: 240810) Posts KRW 26.7B Operating Loss in Q1, Swinging to Deficit Amid Weak Front-End Equipment Orders

Related Posts

[Disclosure] Hanwha Aerospace (012450) Clarifies Market Rumor: “Review on Acquiring Poongsan’s Defense Division Has Been Terminated” Disclosures
[Disclosure] Hanwha Ocean (042660) Secures KRW 507.4B Contract for 3 VLACs from African Shipowner Disclosures
[Disclosure] Samsung Biologics (207940) Discloses Additional CMO Contract Worth KRW 56.7B with European Pharmaceutical Company Disclosures
[Disclosure] SK square (402340) Re-issues Advisory on ’11st Sale’: Driven by Financial Investors, No Terms Finalized Yet Semiconductors
[Disclosure] SK square (402340) Convenes Extraordinary General Meeting for August 14: Onboarding Investment Head Myung-jin Han to the Board Semiconductors
[Disclosure] Celltrion (068270) Announces Relisting due to Stock Retirement, Decreasing Common Shares by 3,011,910 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme